Advanced search
Publication Cover
Infection and Drug Resistance Volume 16, 2023 - Issue
Submit an article Journal homepage
244
Views
5
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis

Hua XiaoNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Xia YuNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Yuanyuan ShangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Ruyan RenNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Yi XueNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Lingling DongNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Liping ZhaoNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
,
Guanglu JiangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaView further author information
&
Hairong HuangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research; Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 217-224 | Received 17 Sep 2022, Accepted 20 Dec 2022, Published online: 10 Jan 2023

References

  • World Health Organization. Global tuberculosis report 2021; 2021. Available from: https://www.who.int/teams/global-tuberculosis-programme/data. Accessed December 21, 2022.
  • Fellous S, Rkain H, Tahiri L, Bouraqadi A, Nassar I, Allali F. Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report. Pan Afr Med J. 2020;36:165. doi:10.11604/pamj.2020.36.165.21689
  • Garg RK, Rizvi I, Malhotra HS, Uniyal R, Kumar N. Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis. Expert Rev Anti Infect Ther. 2018;16:813–831. doi:10.1080/14787210.2018.1540930
  • Kherabi Y, Fréchet-Jachym M, Rioux C, et al. Revised definitions of tuberculosis resistance and treatment outcomes, France, 2006–2019. Emerg Infect Dis. 2022;28:1796–1804. doi:10.3201/eid2809.220458
  • Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology. 2018;23:656–673. doi:10.1111/resp.13304
  • Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–227. doi:10.1126/science.1106753
  • Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev Res. 2019;80:98–105. doi:10.1002/ddr.21498
  • Ardhianto D, Suharjono S, Fatmawati U, Fatmawati U. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients. J Basic Clin Physiol Pharmacol. 2021;32:421–427. doi:10.1515/jbcpp-2020-0415
  • Saeed DK, Shakoor S, Razzak SA, et al. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. BMC Microbiol. 2022;22:62. doi:10.1186/s12866-022-02475-4
  • Wu SH, Chan HH, Hsiao HC, Jou R. Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan. Front Microbiol. 2021;12:754249. doi:10.3389/fmicb.2021.754249
  • Patel H, Pawara R, Pawara K, Ahmed F, Shirkhedkar A, Surana S. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity. Tuberculosis. 2019;117:79–84. doi:10.1016/j.tube.2019.06.005
  • Nguyen TVA, Anthony RM, Bañuls AL, Nguyen TVA, Vu DH, Alffenaar JC. Bedaquiline resistance: its emergence, mechanism, and prevention. Clin Infect Dis. 2018;66:1625–1630. doi:10.1093/cid/cix992
  • Huang Z, Luo W, Xu D, et al. Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorg Med Chem Lett. 2022;71:128824. doi:10.1016/j.bmcl.2022.128824
  • Yao R, Wang B, Fu L, et al. Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis. Microbiol Spectr. 2022;10:e0247721. doi:10.1128/spectrum.02477-21
  • Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.02627-16
  • Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Standard. 2nd ed. document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
  • Clinical and Laboratory Standards Institute. M26-A: Methods for Determining Bactericidal Activity of Antimicrobial Agents. Clinical and Laboratory Standards Institute; 1999.
  • Ngwalero P, Brust JCM, van Beek SW, et al. Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African Patients with rifampin-resistant tuberculosis. Antimicrob Agents Chemother. 2021;65:e0239920. doi:10.1128/AAC.02399-20
  • Perrineau S, Lachâtre M, Lê MP, et al. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23:99–104. doi:10.5588/ijtld.18.0042
  • Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness. Clin Infect Dis. 2021;72(7):1244–1246. doi:10.1093/cid/ciaa877

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.